Answers are grounded in this paper and cite their sources.
Objectives: to evaluate and compare serum adiponectin levels in different phenotypes of polycystic ovary syndrome (PCOS) and to investigate their correlation with endocrine and metabolic parameters. Material and methods: we studied 5 groups of patients: A (n = 20): H (hyperandrogenism) + O (oligoanovulation) + P (polycystic ovary) [classic phenotype]; B (n = 17): H + O [classic phenotype but normal ovaries]; C (n = 15): H + P [Ovulatory phenotype]; D (n = 17): O + P [Normoandrogenic phenotype]; and E (n = 16) control group. Body mass index, waist circumference, waist/hip ratio, blood pressure and hirsutism were evaluated. Serum concentrations of adiponectin, insulin, Creactive protein, SHBG, androgens and lipids were measured. Oral glucose tolerance test was performed. Results: there were no differences between the groups in terms of age and BMI. Total cholesterol, LDL-C and triglyceride levels were higher in phenotype A than in C (P P = 0.03). HOMA-IR, insulin and glucose/insulin ratio were significantly higher in phenotypes A and D vs C and E (P P P < 0.05). Conclusions: adiponectin serum concentrations vary according to the phenotypic expression of PCOS. Our results suggest that adiponectin could be used as a biochemical marker to identify phenotypes at increased metabolic risk.
No takes yet. Share an insight, caveat, or question.
Otta et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: